Biohaven Therapeutics Ltd. has patented new pyrazolo[1,5-a]pyridin-2,3-yl amides acting as potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators.
Satellos Bioscience Inc. has received orphan drug designation and rare pediatric disease designation from the FDA for SAT-3153 for the potential treatment of Duchenne muscular dystrophy (DMD). The first-in-class oral small-molecule therapeutic is designed to restore the innate muscle regeneration process independent of dystrophin and regardless of exon mutation status.
A Design Therapeutics Inc. patent details conjugates consisting of DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence linked to protein binding moiety through oligomeric backbone linker.
Researchers from China Pharmaceutical University and affiliated organizations have reported the discovery and preclinical evaluation of a novel bromodomain and extra-terminal (BET) inhibitor, DDO-8926, being developed for the management of neuropathic pain.
Swiss researchers have gained new insights into the relationship between aging, inflammation, neurodegeneration and cognitive decline. EPFL professor Andrea Ablasser and her team showed that brain aging was driven by microglial activation of the cGAS/STING pathway.
Entrada Therapeutics Inc. has received authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its CTIMP (clinical trial of an investigational medicinal product) application for a phase I clinical trial in healthy volunteers for ENTR-601-44.
A receptor could hold the key to explaining how stress affects behavior, at least under certain circumstances. Scientists from the Korea Advanced Institute of Science and Technology (KAIST) have described how childhood neglect or abuse altered the brain. Stress glucocorticoid hormones caused neuronal damage in mice by increasing the receptor tyrosine kinase MERTK in astrocytes and inducing them to phagocytose excitatory synapses.
Bright Minds Biosciences Inc. has created phenethlyamines acting as 5-HT2A receptor agonists and reported to be useful for the treatment of depression and anxiety disorders.
Non-profit Solve GNE LLC has raised over $2.5 million and announced sponsored research agreements to help advance research in hereditary inclusion body myopathy (HIBM), or GNE myopathy (GNEM).
Researchers from Universita degli Studi di Pavia and affiliated organizations have presented the discovery of a novel sigma-1 receptor (S1R) antagonist, RC-752, being developed as an antinociceptive agent for the treatment of neuropathic pain.
RSS
